International Clinical Trial: A Single-Center, Phase II Clinical Study of Neoadjuvant Sacituzumab Tirumotecan in Combination with Tislelizumab for Resectable Stage IIIIIB Squamous Non-Small Cell Lung Cancer (neoTropIm)

Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134020) titled 'A Single-Center, Phase II Clinical Study of Neoadjuvant Sacituzumab Tirumotecan in Combination with Tislelizumab for Resectable Stage IIIIIB Squamous Non-Small Cell Lung Cancer (neoTropIm)' on Oct. 10.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The second affiliated hospital of Zhejiang University school of medicine

Condition: Squamous non-small cell lung cancer (squamous NSCLC)

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-10-15

Target Sample Size: Single-arm study group:35;

Countries of Recruitment: China

To know more, visit https://www...